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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To evaluate whether automated systems for the early detection of sepsis can reduce the time to appropriate treatment and improve
clinical outcomes in critically ill patients in the ICU.
B A C K G R O U N D
Description of the condition
Sepsis is a clinical syndrome defined as “life-threatening organ
dysfunction caused by a dysregulated host response to infection”
(Gotts 2016; Singer 2016). The criteria for the diagnosis of sepsis
have evolved over time and are generally defined by international
consensus groups (ACCP/SCCM1992; Levy 2003; Singer 2016).
If left untreated, sepsis can lead to septic shock (defined as “va-
sopressor requirement to maintain a mean arterial pressure of 65
mmHg or greater and serum lactate level greater than 2 mmol/
L (> 18 mg/dL) in the absence of hypovolaemia” (Singer 2016);
and previously defined as severe sepsis and hypotension that is not
reversed by fluid resuscitation (Dellinger 2013)), when mortality
can exceed 50% (Gotts 2016). Patients with sepsis often require
admission to the intensive care unit (ICU) and the incidence of
sepsis in ICU patients initially admitted for other critical illnesses
is also high (20% to 70% of ICU patients in Europe, with con-
siderable variance by country) (Vincent 2006). The diagnosis of
sepsis is challenging and time consuming, and often requires the
combination of information from several sources (e.g. patient his-
tory, laboratory data, and physiological data) at regular intervals
(Cohen 2015). The complexity of diagnosis combined with the
degree of illness results in a significant cost for treating sepsis in
the ICU. For example, the cost of treating each patient with sepsis
in the ICU was recently estimated as approximately EUR 29,000
in the Netherlands (Koster-Brouwer 2014), or GBP 20,000 in the
UK (UK Sepsis Trust 2013).
Description of the intervention
Automated monitoring systems provide a means of monitoring
patient data continuously, and can facilitate the assembly of data
from unconnected information systems (Hooper 2012). These
tools are variously referred to as alert systems, detection systems
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and monitoring systems (Makam 2015). In essence, the systems
process clinical data - that are routinely collected - to identify sep-
sis according to predetermined diagnostic thresholds, and include
an electronic means of alerting staff. Although the algorithms (i.e.
criteria) used to identify sepsis vary between the different auto-
mated systems (Buck 2014; Nachimuthu 2012), their key feature
is an ability tomonitor one ormore electronic systems (e.g. patient
electronic health records) for potential indicators of sepsis. For ex-
ample, a systemmay ’listen’ for modified systematic inflammatory
response syndrome (SIRS) criteria (Hooper 2012), although SIRS
criteria have recently been deemed to have inadequate specificity
and sensitivity for the detection of sepsis (Singer 2016). Follow-
ing detection of potential sepsis, the system should provide an au-
tomated notification (e.g. via email, phone message or pager) to
the relevant physician or nurse, flagging the requirement for clin-
ical evaluation and potential initiation of therapy (Hooper 2012;
Koenig 2011). The use of electronic early-recognition tools has
previously been validated in the critical care setting for detection
of acute respiratory distress syndrome (ARDS) (Koenig 2011).
Potential adverse effects of automated systems might include the
failure to detect sepsis and alarm fatigue (i.e. where frequent false
alarms cause staff to ignore notification of potential sepsis).
How the intervention might work
Automated detection systems monitor patient data continuously
to facilitate the early detection of sepsis in the ICU. The diagnosis
of sepsis or septic shock is particularly time-sensitive, as the length
of time until initiation of appropriate antimicrobial therapy or
fluid resuscitation is a critical determinant of survival in these pa-
tients (Dellinger 2013; Kumar 2006; Rivers 2001; Yealy 2014).
Therefore, guidelines recommend early fluid resuscitation of the
septic patient within six hours of recognition of sepsis, and ad-
ministration of broad-spectrum antibiotics within one hour of the
recognition of septic shock or severe sepsis without septic shock
(Dellinger 2013). Automated detection systems offer the possibil-
ity of monitoring patients in ’real-time’ (Meurer 2009), and can
alert the relevant physicians or nurses (e.g. by email or pager) to
the need for timely clinical evaluation and potential initiation of
treatment.
Why it is important to do this review
Although the rate of mortality from sepsis has improved (
Kaukonen 2014; McPherson 2013), national audits indicate that
clinical standards relevant to the management of patients with
sepsis are not being met, despite ongoing education programmes
(CEM 2012). The UK Parliamentary Ombudsman recently pub-
lished a detailed report that identified common themes in 10
case studies of patients that died following sepsis (Parliamentary
Ombudsman 2013). Failings were identified throughout the care
pathway, from carrying out a timely initial assessment and identi-
fying the source of infection, to adequate monitoring and timely
initiation of treatment (Parliamentary Ombudsman 2013). Auto-
matedmonitoring systems for the detection of sepsis may facilitate
earlier detection and treatment of sepsis in the ICU, potentially
increasing adherence to clinical standards and improving patient
outcomes.
Additionally, sepsis is themost expensive condition treated in hos-
pitals, accounting for approximately 5% of total hospitalization
costs and an overall annual cost of USD 20.3 billion in the USA
(Torio 2011), and more than GBP 2.5 billion in the UK (UK
Sepsis Trust 2013). Early detection of sepsis via automated systems
and subsequent timely intervention may reduce treatment costs
and overall resource use (Rivers 2001; Yealy 2014). The UK Sepsis
Trust estimates that there are more than 100,000 hospitalizations
per year for sepsis, and that achieving 80% delivery of basic stan-
dards of care could result in a potential cost saving of GBP 170
million per year, even after allowing for increased survival-related
costs (UK Sepsis Trust 2013).
Finally, it is now recognized that sepsis is associated with a signif-
icant long-term mortality, morbidity and a reduction in health-
related quality of life (Winters 2010), thus reinforcing the impor-
tance of early effective treatment from both a patient and resource
utilization perspective. In summary, there is clear rationale to syn-
thesize the evidence relating to the use of automated systems for
the detection of sepsis.
O B J E C T I V E S
To evaluate whether automated systems for the early detection of
sepsis can reduce the time to appropriate treatment and improve
clinical outcomes in critically ill patients in the ICU.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include randomized controlled trials (RCTs) reported as
full text, or published as abstract only, and unpublished data. We
will not exclude unblinded studies. We will exclude cross-over
studies as it would not be feasible to evaluate automated monitor-
ing followed by standard care (or vice-versa) in the same patient as
the detection of sepsis requires treatment. We will exclude quasi-
RCTs (studies using inadequate methods for randomization such
as date of birth of participant or date of ICU admission).
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Types of participants
We will include participants of any age who are admitted to in-
tensive or critical care units for critical illness (including, but not
limited to postsurgery, trauma, stroke, myocardial infarction, ar-
rhythmia, burns, and hypovolaemic or haemorrhagic shock). We
will exclude participants who are admitted with confirmed sepsis.
Types of interventions
We will include studies that randomize participants to receive
monitoring for sepsis using an automated system versus standard
care (i.e. systems where paper-based or other formats of observa-
tion charts are reviewed by staff directly). We define an automated
system as any process capable of screening patient records or data
(one or more systems) automatically at intervals for markers or
characteristics that are indicative of sepsis. The parameters/algo-
rithm used by the system (for example, the thresholds of blood
pressure indicative of hypotension or the nature of the biomarkers
employed) may vary. However, if the system identifies a potential
case of sepsis, it should flag the patient’s record and alert the rele-
vant healthcare professional (via email, pager or phone message).
Types of outcome measures
Primary outcomes
1. Time to initiation of antimicrobial therapy*
2. Time to initiation of fluid resuscitation*
3. 30-day mortality
*Time to initiation starts at the time of admission.
Note: studies are not required to distinguish between sepsis that
is detected via standard care pathways and sepsis detected via the
automated system in the intervention group; if studies employ ad-
equate control groups and sample sizes, and if automated mon-
itoring confers a benefit, a difference between groups should be
detectable.
Secondary outcomes
1. Length of stay in ICU
2. Failed detection of sepsis during ICU stay
3. Quality of life measured at the latest available time point
post-discharge from ICU (preferred measure SF-36 then EQ-5D)
Search methods for identification of studies
Electronic searches
We will search the Cochrane Central Register of Controlled
Trials (CENTRAL); MEDLINE (OvidSP); Embase (OvidSP);
CINAHL (EBSCO host); ISIWeb of Science; and LILACS (BIR-
ERME interface). We will adopt the MEDLINE search strat-
egy for all of the other databases (see Appendices for details of
search terms). We will also conduct a search of Clinicaltrials.gov (
www.clinicaltrials.gov), and theWorld Health Organization trials
portal (www.who.int/ictrp/en/). We will search all databases from
their date of inception to present, with no restriction on country
or language of publication.
Searching other resources
We will check the bibliography of all relevant primary studies and
review articles to identify additional studies that may be relevant
to the review. We will consult grey literature as appropriate.
Data collection and analysis
We will conduct the review according to this published protocol
and report any deviations from it in the ’Differences between pro-
tocol and review’ section of the systematic review.
Selection of studies
Using Covidence (Covidence 2015), two review authors (DE,
SL) will independently screen titles and abstracts arising from the
searches, for possible inclusion in the review; we will retrieve and
assess the full-text articles of these potentially relevant studies and
two review authors (DE, SL) will independently identify: a) stud-
ies for inclusion in the review; and b) ineligible studies; record-
ing the reasons for exclusion in the ’Characteristics of excluded
studies’ table. We will resolve disagreements by discussion or, if
required, through consultation with a third author (PA or AS).We
will identify and exclude duplicate records, and multiple reports
of the same study will be collated so that the study is the unit
of interest. We will summarize the results of the selection process
using a PRISMA flow diagram (Moher 2009).
Data extraction and management
We will use a data collection form to collect study characteristics
and outcome data from the included studies; the form will be
piloted on at least one study. One review author will extract the
following information:
1. methods: study design; total duration of study; number of
study centres and location; study setting; date of study;
2. participants: number of participants that were: a) randomly
assigned, b) discontinued the study, and c) excluded from the
analyses after randomization; condition and severity of
condition; inclusion and exclusion criteria;
3. intervention: intervention, comparator, algorithm/criteria
used by the automated system;
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4. outcomes: primary and secondary outcomes including
details of time points;
5. other information: trial funding and potential conflicts of
interest of authors.
Two review authors (DE, SL) will independently extract outcome
data from the included studies. We will resolve disagreements by
discussion or involvement of a third author (PA or AS). One re-
view author (DE) will transfer the data into Review Manager 5
(RevMan 2014), and the accuracy of the data will be confirmed
by comparison with individual studies. A second review author
(SL) will perform a spot check of study characteristics for accuracy
against the original trial reports.
Assessment of risk of bias in included studies
Two review authors (DE and SL) will independently assess the risk
of bias for each study according to criteria outlined in theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreements by discussion or by involving
another author (PA or AS). We will assess the risk of bias for the
following domains:
1. random sequence generation;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessment;
5. incomplete outcome data;
6. selective outcome reporting;
7. other bias.
For each domain, we will grade the risk of bias as high, low or
unclear, and provide justification for our judgement in the ’risk of
bias’ table. We will summarize the risk of bias judgements across
the included studies for each of the domains listed; wewill present a
summary ’Risk of bias’ figure.We will consider blinding separately
for different key outcomes where necessary (e.g. for unblinded
outcome assessment, risk of bias for a patient-reported outcome
such as quality of lifemay be very different from that formortality).
If information relating to risk of bias is based on unpublished data
or correspondence with a study investigator, we will note this in
the ’Risk of bias’ table.When considering treatment effects, wewill
take into account the risk of bias for the studies that contributed
to each outcome.
Measures of treatment effect
We will analyse dichotomous data (e.g. mortality, failed detection
of sepsis) as risk ratios or Mantel-Haenszel odds ratios when the
outcome is an infrequent event (i.e. less than 10%), or Peto odds
ratios when the outcome is very rare (i.e. less than 1%), and use
95% confidence intervals. We will analysecontinuous data (e.g.
quality of life, length of ICU stay) as mean difference or standard-
ized mean difference, depending on whether the same scale is used
to measure an outcome, again with 95% confidence intervals. We
will enter data presented as a scale with a consistent direction of ef-
fect across studies. We will extract hazard ratios and standard error
for time-to-event data (e.g. time to initiation of antibiotics/fluid
resuscitation) and we will perform meta-analysis using generic in-
verse variance methodology (Higgins 2011).
Unit of analysis issues
If multiple trial arms are reported in a single trial, we will only
include the relevant arms. With the exception of time-to-event
data, if two comparisons are combined in the same meta-analysis
(e.g. intervention A versus standard care and intervention B versus
standard care), we will halve the control group to avoid double-
counting (Higgins 2011). We will deal with studies with a cluster
design according to the advice in section 16.3 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Dealing with missing data
Where possible, we will contact study investigators or sponsors
to obtain missing outcome data or verify important study char-
acteristics. If this is not possible, and missing data are considered
likely to introduce serious bias, we will use available case data if
necessary, rather than imputed values. We will explore the impact
of including such studies in the overall assessment of results by a
sensitivity analysis. Any assumptions and imputations to handle
missing data will be clearly described and the effect of imputation
will be explored by sensitivity analyses.
Where possible, missing standard deviations will be computed
fromother statistics such as standard errors, confidence intervals or
P values, according to the methods recommended in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
If standard deviations cannot be calculated, they will be imputed
(e.g. from other studies in the meta-analysis).
Where studies report mortality at a time point other than 30 days,
we will contact the authors to see if 30-day data are available, or
incorporate the additional time point in our analysis, recording
this in the ’Differences between protocol and review’ section.
Assessment of heterogeneity
We will use the I2 statistic to measure heterogeneity among the
trials included in each analysis. Where moderate or significant
heterogeneity is found to be present (i.e. I2 statistic ≥ 40%), we
will report it and explore possible causes by analysis of prespecified
subgroups. The Chi² test will be interpreted as indicating evidence
of statistical heterogeneity when the P value is equal to or less than
0.10.
Assessment of reporting biases
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If we are able to pool data from more than 10 trials, we will
explore possible small study and publication biases by creating and
examining a funnel plot.
To assess within-study reporting bias of outcomes, we will check
trial protocols against published reports. For studies published
after 1 July 2005, we will screen the Clinical Trial Register at
the International Clinical Trials Registry Platform of the World
Health Organization (http://apps.who.int/trialssearch) and Clin-
icaltrials.gov (https://clinicaltrials.gov/) for the trial protocol. We
will evaluate whether selective reporting of outcomes is present.
Data synthesis
We will undertake meta-analyses only where this is meaningful
(i.e. if the treatments, participants, criteria for the diagnosis of
sepsis, and the underlying clinical question are similar enough for
pooling to make sense) and where measures of heterogeneity indi-
cate that pooling of results is appropriate. For example, the criteria
for the diagnosis of sepsis have evolved (ACCP/SCCM1992; Levy
2003; Singer 2016), and will likely influence the populations of
participants examined by relevant studies from different periods.
It may not be meaningful to incorporate RCTs with different def-
initions of sepsis in the same meta-analysis. We will use a random-
effects statistical model.
’Summary of findings’ table
We will use the principles of the GRADE system (Guyatt 2008),
to assess the quality of the body of evidence associated with the fol-
lowing outcomes in our review: time to initiation of antimicrobial
therapy, time to initiation of fluid resuscitation, 30-day mortality,
failed detection of sepsis, length of stay in ICU, failure to detect
sepsis, and quality of life (postdischarge).
Two authors (DE, SL) will independently assess the quality of the
evidence. We will use the five GRADE considerations (study lim-
itations, inconsistency, imprecision, indirectness and publication
bias) to assess the quality of the body of evidence as it relates to the
studies that contribute data to the meta-analyses for the prespec-
ified outcomes. The GRADE approach appraises the quality of a
body of evidence based on the extent to which one can be confi-
dent that an estimate of effect or association reflects the item being
assessed. The quality of a body of evidence takes into consideration
within-study risk of bias (methodologic quality) (Guyatt 2011b),
the directness of the evidence (Guyatt 2011c), heterogeneity of the
data (Guyatt 2011d), precision of effect estimates (Guyatt 2011e),
and risk of publication bias (Guyatt 2011f). We will use methods
and recommendations described in Chapter 8 (section 8.5 and
8.7), Chapter 11 and Chapter 13 (section 13.5) of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011;
Schünemann 2011), using GRADEpro software. We will justify
all decisions to downgrade the quality of studies using footnotes
and we will make comments to aid readers’ understanding of the
review where necessary.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses:
1. Severity of sepsis: e.g. sepsis versus septic shock (defined as
either: a) vasopressor requirement to maintain a minimum mean
arterial pressure of 65 mmHg or greater and a serum lactate level
greater than 2 mmol/L (> 18 mg/dL) in the absence of
hypovolaemia (Singer 2016); or b) severe sepsis plus hypotension
not reversed by fluid resuscitation (Dellinger 2013)). We note
that more recently, it has been determined that sepsis does not
follow a continuum through severe sepsis to septic shock (Singer
2016). Therefore, participants who are considered as having
’severe sepsis’ (previously defined as acute organ dysfunction
secondary to infection (Dellinger 2013)), will be considered as
having ’sepsis’ for the purpose of this review.
2. Algorithms: (i.e. criteria) for detection. It is possible that
the algorithms employed by different automated detection
systems could vary substantially, and could represent a source of
heterogeneity. We will explore potential algorithm-derived
heterogeneity by subgroup analysis if common features can be
identified.
We will perform subgroup analyses for each of the primary out-
comes (where relevant). We will use the formal test for subgroup
interactions in Review Manager 5 (RevMan 2014). The magni-
tude of the effects will be compared between the subgroups by
means of assessing the overlap of the confidence intervals of the
summary estimate. Non-overlap of the confidence intervals indi-
cates statistical significance.
Sensitivity analysis
We plan to carry out the following sensitivity analyses.
1. Unpublished data (i.e. no peer-reviewed full-text paper
available).
2. Trials with inadequate or unclear methods of random
sequence generation or allocation concealment (i.e. high risk or
unclear risk of selection bias).
3. Trials with inadequate or unclear methods of blinding of
outcome assessor (i.e. high risk or unclear risk of performance
bias); this subanalysis may be particularly relevant to trials
reporting quality of life (i.e. a subjective outcome).
4. Studies with missing data (e.g. to examine the effect of
imputed data or data based on assumptions).
5. Trials that use outdated criteria for the diagnosis/severity of
sepsis (i.e. definitions used prior to those reported by Singer
2016)
The category of bias (e.g. high/unclear/low risk) will be deter-
mined during the ’Risk of bias’ assessment, the criteria for this are
described in theCochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011). Sensitivity analyses will be performed
using a fixed-effect model.
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A P P E N D I C E S
Appendix 1. MEDLINE (Ovid SP) search strategy
1 (((automated or electronic) adj3 (monitoring or detect*)) or (early adj3 (monitoring or detect* or treat* or recogn* or initiat*)) or
(pre?defined adj3 criteria) or (system* adj3 (paper or computer or monitoring or detection or automated))).mp. (189259)
2 Sepsis/ or Shock, Septic/ or (septic* or sepsis).mp. (127937)
3 1 and 2 (2867)
4 ((randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or drug therapy.fs. or randomly.ab. or
trial.ab. or groups.ab.) not (animals not (humans and animals)).sh. (2852749)
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